Navigation Links
U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
Date:5/13/2013

RARITAN, N.J., May 13, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for simeprevir (TMC435), an investigational NS3/4A protease inhibitor administered as a 150 mg capsule once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease.

Hepatitis C virus (HCV) is a blood-borne infectious disease of the liver that affects approximately 3.2 million people in the United States. When left untreated over time, HCV can cause significant damage to the liver, including cirrhosis.

"Hepatitis C is a complex disease and Janssen is committed to working with the HCV community, caregivers and healthcare systems to address this global epidemic," said Gaston Picchio , Hepatitis Disease Area Leader, Janssen Research & Development. "We are pleased that the FDA has granted simeprevir Priority Review, as it is a significant step forward in making this therapy available to physicians and their hepatitis C patients."

The FDA grants Priority Review to medicines that may offer major advances in care or provide a treatment option where no adequate therapy exists. Under the Prescription Drug User Fee Act, FDA review will begin approximately 60 days after receipt of the application and will aim to be complete within six months from when the review period begins.

The regulatory submission for simeprevir is supported in part by data from three pivotal Phase 3 studies: QUEST-1 and QUEST-2 in treatment-naive patients and PROMISE in patients who have relapsed after prior interferon-based treatment. Janssen also recently submitted simeprevir for marketing authorization to regulatory authorities in Japan and '/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
2. Community Foundation Announces $2.6 Million In Grants From Centinela Medical Funds
3. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
4. European Commission Grants Orphan Medicinal Product Designation for Emmaus Medicals Sickle Cell Treatment
5. FDA Grants Orphan Drug Designation To GeNO LLC For Use Of Inhaled Nitric Oxide In Treatment Of Persistant Pulmonary Hypertension Of The Newborn (PPHN)
6. Rep. Fattah Announces More Than $10.7 Million in Grants for Neuroscience, Scientific and Medical Research in Philadelphia
7. U.S. FDA Grants Priority Review to Bedaquiline (TMC207) for Multi-Drug Resistant Tuberculosis Treatment
8. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
9. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
10. As Global Telemedicine Market Reaches $2.5 Billion, Industry Leaders Gather in San Diego to Discuss Grants, Funding, Vendor Selection, Credentialing, and More
11. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... WASHINGTON , March 4, 2015  Vanda ... today announced top-line results of the Phase II ... and efficacy of tradipitant as a monotherapy in ... atopic dermatitis. Despite a highly significant and clinically ... from baseline, p<0.0001) as measured on a 100mm ...
(Date:3/4/2015)... 2015 Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... regenerative medicine, today announced that Pedro Lichtinger , ... Bell ® of the New York Stock Exchange ... as an NYSE MKT listed company on October 8, ... a trusted partner to Asterias Biotherapeutics, and we are ...
(Date:3/4/2015)... InfuSystem Holdings, Inc. (NYSE MKT: INFU), a ... for the U.S. healthcare industry, today announced that it ... results on Monday, March 9, 2015 after the market ... conference call for investors on Monday, March 9, 2015 ... and full year 2014 performance and results.  To participate ...
Breaking Medicine Technology:Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 2Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 3
... Market to Demonstrate Test,s Potential for ... Rapid ... DIAG) and Applied Biosystems Inc. (NYSE: ABI ) today,announced the launch ... searches for a unique gene expression signature,identified by DiaGenic using a custom ...
... Have Other Important Benefits, Says CRN-, WASHINGTON, ... Study II, to be released at the American ... the November 12,issue of the Journal of the ... vitamin E and C supplementation on cardiovascular,events in ...
Cached Medicine Technology:Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test 2Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test 3Physicians' Health Study II Finds No Magic Bullet for Preventing Cardiovascular Disease 2Physicians' Health Study II Finds No Magic Bullet for Preventing Cardiovascular Disease 3Physicians' Health Study II Finds No Magic Bullet for Preventing Cardiovascular Disease 4
(Date:3/4/2015)... With the growing influence of movies, television, video games and ... adults, combined with the increasingly frantic lifestyle of modern parents, ... up with what kids are into these days. It seems ... daily basis. , The same is also true for drugs ... to discreetly talk about them, are constantly changing. These tips ...
(Date:3/4/2015)... More than a year after announcing ... with low testosterone treatments ( http://www.testosteronelawsuithub.com/ ), the U.S. ... now require manufacturers to warn patients that this class ... and strokes. In a Drug Safety Communication ... it was requiring testosterone manufacturers to update the drugs’ ...
(Date:3/4/2015)... 04, 2015 Vancouver chiropractic clinic, ... two awards in the prestigious Vancouver Courier “Stars ... 27, 2015. The company secured third place in ... the “Best Registered Massage Therapist” category. , ... in Canada, The Vancouver Courier is a semiweekly ...
(Date:3/4/2015)... York, NY (PRWEB) March 04, 2015 ... the centerfold of The San Francisco Chronicle with a ... of 500,000 readers. Its digital component is distributed nationally ... network of top news sites and partner outlets. To ... here. , Milorganite is composed of heat-dried ...
(Date:3/4/2015)... 2015 State officials have awarded $82,500 ... of Public Health at Georgia State University, to support ... by Georgia’s Division of Family and Children Services (DFCS) ... Call Center. , The 1-800-CHILDREN Helpline is a ... and referral services that promote the wellbeing of children ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4Health News:Backs in Action Receives Two Awards in The Vancouver Courier Readers’ Choice Awards 2015 2Health News:State Funds Child Abuse Helpline Housed At Georgia State 2
... , , , , , , ... Medical,International Limited (NYSE: MR ), a leading developer, ... at its annual general meeting of shareholders held in Hong ... the meeting, Mindray Medical International,s shareholders approved the,re-election of directors ...
... causes more pain than vodka, study finds , FRIDAY, Dec. ... a common indulgence -- and nasty hangovers a common consequence. ... lighter-colored beverages, they might feel a little better the next ... contain more toxic properties that provoke more painful hangovers than ...
... , , , NEWPORT BEACH, Calif., Dec. 18 ... announced today that it has given notice that it is ... Cumulative Convertible Preferred Stock ("Series B Preferred Stock") (NHP-PB - ... price per share of $103.875 plus an amount equal to ...
... thoughts may help explain interpersonal problems , FRIDAY, Dec. ... are less active than expected when they,re engaged in ... difficulties, say British researchers. , Using functional MRI, they ... whom had autism, while they were asked questions about ...
... CentraCare president is new chair , ST. PAUL, Minn., Dec. ... systems, recently elected or re-elected the following members to its board for ... Chair - Terence Pladson, M.D., president, CentraCare Health System, ... CEO, Queen of Peace Hospital, New Prague, Secretary/treasurer - ...
... , , HOUSTON, Dec. 18 ... largest provider of deathcare products and services in North America, ... has extended the expiry time of its offer (the "Offer") ... and outstanding common shares in the capital of Keystone North ...
Cached Medicine News:Health News:Mindray Medical International Limited Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting 2Health News:For a Lighter Hangover, Avoid Darker Drinks 2Health News:For a Lighter Hangover, Avoid Darker Drinks 3Health News:For a Lighter Hangover, Avoid Darker Drinks 4Health News:Nationwide Health Properties, Inc. Announces the Redemption of All Outstanding Shares of 7.75% Series B Cumulative Convertible Preferred Stock 2Health News:Brain Imaging Sheds Light on Social Woes Related to Autism 2Health News:Minnesota Hospital Association Elects, Re-Elects Members to Board 2Health News:Service Corporation International Extends Offer for Keystone North America Inc. 2Health News:Service Corporation International Extends Offer for Keystone North America Inc. 3
McIntyre-Binkhorst Cannula have a smooth blunt tip end opening....
Army navy retractor set....
Sharp. 4 mm wide. Hand-Held...
Adsons bayonet forceps....
Medicine Products: